StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) stock

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.57−0.13 (-3.51%)

Close on Nov 18, 2026Market cap $99.44MP/E –Yield –

Unicycive Therapeutics cash

Cash and short-term investments held at the end of each period.

Unicycive Therapeutics's cash was $61.43M at Jun 30, 2026. For fiscal 2025 it was $41.27M, up 57.9% from the year before. The highest annual figure on record is $41.27M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$41.27M+57.9%
FY2024Dec 31, 2024$26.14M+169.5%
FY2023Dec 31, 2023$9.70M+2032.1%
FY2022Dec 31, 2022$455.00K-97.3%
FY2021Dec 31, 2021$16.58M+110426.7%
FY2019Dec 31, 2019$15.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$61.43M+175.1%
Q1 FY2026Mar 31, 2026$54.59M+176.1%
Q4 FY2025Dec 31, 2025$41.27M+57.9%
Q3 FY2025Sep 30, 2025$42.70M+32.0%
Q2 FY2025Jun 30, 2025$22.33M-46.6%
Q1 FY2025Mar 31, 2025$19.77M-59.6%
Q4 FY2024Dec 31, 2024$26.14M+169.5%
Q3 FY2024Sep 30, 2024$32.35M+125.5%
Q2 FY2024Jun 30, 2024$41.78M+122.0%
Q1 FY2024Mar 31, 2024$48.93M+101.1%
Q4 FY2023Dec 31, 2023$9.70M+2032.1%
Q3 FY2023Sep 30, 2023$14.35M+104.6%
Q2 FY2023Jun 30, 2023$18.82M+78.0%
Q1 FY2023Mar 31, 2023$24.33M+78.6%
Q4 FY2022Dec 31, 2022$455.00K-97.3%
Q3 FY2022Sep 30, 2022$7.01M-61.1%
Q2 FY2022Jun 30, 2022$10.57M+1057200.0%
Q1 FY2022Mar 31, 2022$13.62M+9165.3%
Q4 FY2021Dec 31, 2021$16.58M+26215.9%
Q3 FY2021Sep 30, 2021$18.01M+1801000.0%
Q2 FY2021Jun 30, 2021$1.00K-93.3%
Q1 FY2021Mar 31, 2021$147.00K–
Q3 FY2020Sep 30, 2020$63.00K–
Q2 FY2020Jun 30, 2020$1.00K–
Q4 FY2019Dec 31, 2019$15.00K–

More Unicycive Therapeutics figures

See a number that looks wrong?